Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TFEB
REST API REST API
Homo sapiens
TFEB is differentially expressed in 282 experiments: 122 organism parts: ovary, liver, ... (120 more);, 223 disease states: normal, control, ... (221 more);, 102 cell types 381 cell lines 34 compound treatments and 68 other conditions.
Synonyms TCFEB, bHLHe35
Orthologs Q4H369_CIOIN (Ciona intestinalis)   tfeb (Danio rerio)   TFEB (Gallus gallus)   TFEB (Bos taurus)   Tfeb (Rattus norvegicus)   Tcfeb (Mus musculus)   tfeb (Xenopus laevis)   TFEB (Canis familiaris)   Mitf (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term humoral immune response, DNA binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, transcription factor complex, positive regulation of transcription, DNA-dependent, embryonic placenta development, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
InterPro Term HLH_DNA-bd, bHLH_ZIP_TF_MiT/TFE
UniProt Accession Q709A8, Q709A9, Q86WB1, P19484, B0QYS7, B0QYS6, B1AKA9, B1AKB2, B1AKB1, B1AKB4, B1AKB5
Search EB-eye ENSG00000112561
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (36 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-5823, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
C7H2-S27(ZR)
1
E-GEOD-22152
375 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-120, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-5099, E-GEOD-3982, E-GEOD-360
2
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
naive T cell
1
E-GEOD-1460
epidermal keratinocyte
1
E-GEOD-2822
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-20168, E-MTAB-62, ... (61 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
Raji Burkitt's lymphoma
2
E-AFMX-5, E-TABM-145
chronic myelogenous leukemia
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lymphoma
2
E-MTAB-37, E-MTAB-62
osteosarcoma
2
E-MTAB-37, E-MTAB-62
217 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
none
3
5
E-TABM-782, E-GEOD-412, E-TABM-868, E-GEOD-5824, E-GEOD-20719, ... (8 experiments)
lipopolysaccharide
1
2
E-TABM-868, E-GEOD-3720, E-MEXP-1958
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
no estradiol
1
E-GEOD-20081
vanadium pentoxide
1
E-GEOD-5339
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-601, E-GEOD-17347, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-4425, E-MEXP-1273, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19136, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922, E-TABM-147

Processing time: 0.323 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM